Cytori Therapeutics (CYTX) Receives News Sentiment Rating of 0.24

News stories about Cytori Therapeutics (NASDAQ:CYTX) have been trending somewhat positive on Monday, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytori Therapeutics earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.3401937534409 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Cytori Therapeutics (NASDAQ CYTX) traded down $0.03 during midday trading on Monday, hitting $0.35. The stock had a trading volume of 1,921,600 shares, compared to its average volume of 3,448,922. The company has a market capitalization of $12.43, a price-to-earnings ratio of -0.39 and a beta of 2.72. Cytori Therapeutics has a one year low of $0.22 and a one year high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.02. The company had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.04 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. During the same quarter last year, the company earned ($0.26) earnings per share. equities analysts anticipate that Cytori Therapeutics will post -0.62 EPS for the current year.

A number of brokerages have recently weighed in on CYTX. B. Riley reiterated a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th. Zacks Investment Research lowered Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, Maxim Group set a $5.00 target price on Cytori Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th.

In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total transaction of $38,000.00. Following the sale, the insider now owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cytori Therapeutics (CYTX) Receives News Sentiment Rating of 0.24” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Insider Buying and Selling by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply